National Institutes of Health: Nasopharyngeal Neoplasms trials

The registry lists 11 Nasopharyngeal Neoplasms studies with National Institutes of Health as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 2Phase 2 6No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon CancerCompletedNCT02961374Phase 2Results posted
• Curcumin in Treating Patients With Familial Adenomatous PolyposisCompletedNCT00641147Phase 2Results posted
• Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal CancerCompletedNCT00408694Phase 2Results posted
• Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous PolyposisCompletedNCT00033371Phase 2Results posted
• Environmental and Genetic Determinants of NPCTerminatedNCT01257100
• Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC FamiliesTerminatedNCT00393224
• Family Study of Head and Neck Cancers in TaiwanCompletedNCT00342147
• Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal CancerCompletedNCT00305734Phase 2
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• Peptide Vaccine to Prevent Recurrence of Nasopharyngeal CancerCompletedNCT00078494Phase 1